GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » Price-to-Owner-Earnings

Foghorn Therapeutics (Foghorn Therapeutics) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-07), Foghorn Therapeutics's share price is $6.01. Foghorn Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Foghorn Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


FHTX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), Foghorn Therapeutics's share price is $6.01. Foghorn Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.20. Therefore, Foghorn Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-07), Foghorn Therapeutics's share price is $6.01. Foghorn Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.20. Therefore, Foghorn Therapeutics's PE Ratio without NRI for today is At Loss.


Foghorn Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Foghorn Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics Price-to-Owner-Earnings Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Foghorn Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Foghorn Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Foghorn Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foghorn Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's Price-to-Owner-Earnings falls into.



Foghorn Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Foghorn Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.01/-3.28
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foghorn Therapeutics  (NAS:FHTX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Foghorn Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Foghorn Therapeutics (Foghorn Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
500 Technology Square, Suite 700, Cambridge, MA, USA, 02139
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Executives
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr. director 800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Carlos Costa officer: Chief People Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie officer: Chief Strategy/Bus Ops Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia officer: Chief Legal Officer 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco officer: Chief Scientific Officer 100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority 10 percent owner 211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Steven F. Bellon officer: See Remarks 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Jose Baselga director 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139